| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,688,925 | 29 | 100 |
| Ganot Ilan | director | 0 | $0 | 5 | $82,374 | $-82,374 |
| Herzich Paul | Chief Technology Officer | 0 | $0 | 4 | $274,077 | $-274,077 |
| Brooks Gabriel | Chief Medical Officer | 0 | $0 | 4 | $288,242 | $-288,242 |
| Hanrahan Jessie | Chief Regulatory Officer | 0 | $0 | 4 | $297,329 | $-297,329 |
| Tan Kevin | CFO & Treasurer | 0 | $0 | 4 | $329,507 | $-329,507 |
| Howton David T | Chief Operating Officer | 0 | $0 | 4 | $433,538 | $-433,538 |
| Cumbo Alexander | President and CEO | 0 | $0 | 4 | $983,857 | $-983,857 |
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing …
Over the last 12 months, insiders at Solid Biosciences Inc. have bought $0 and sold $2.69M worth of Solid Biosciences Inc. stock.
On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $24.98M and sold $634,759 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,860 shares for transaction amount of $9,924 was made by Kahn Clare (director) on 2025‑03‑11.
| 2026-10-19 | Sale | Brooks Gabriel | Chief Medical Officer | 4,374 0.0039% | $5.62 | $24,582 | +4.73% | |
| 2026-02-18 | Sale | Cumbo Alexander | President and CEO | 16,644 0.021% | $5.82 | $96,923 | +29.73% | |
| 2026-02-18 | Sale | Howton David T | Chief Operating Officer | 7,469 0.0094% | $5.82 | $43,494 | +29.73% | |
| 2026-02-18 | Sale | Tan Kevin | CFO & Treasurer | 5,404 0.0068% | $5.82 | $31,469 | +29.73% | |
| 2026-02-18 | Sale | Brooks Gabriel | Chief Medical Officer | 0 – | $5.82 | $0 | +29.73% | |
| 2026-02-18 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 4,134 0.0052% | $5.82 | $24,074 | +29.73% | |
| 2026-02-18 | Sale | Herzich Paul | Chief Technology Officer | 3,616 0.0046% | $5.82 | $21,057 | +29.73% | |
| 2026-02-18 | Sale | Ganot Ilan | director | 2,658 0.0034% | $5.82 | $15,478 | +29.73% | |
| 2026-02-04 | Sale | Cumbo Alexander | President and CEO | 48,913 0.062% | $6.44 | $315,093 | +14.72% | |
| 2026-02-04 | Sale | Howton David T | Chief Operating Officer | 18,894 0.024% | $6.44 | $121,713 | +14.72% | |
| 2026-02-04 | Sale | Tan Kevin | CFO & Treasurer | 14,783 0.0187% | $6.44 | $95,231 | +14.72% | |
| 2026-02-04 | Sale | Brooks Gabriel | Chief Medical Officer | 12,616 0.016% | $6.44 | $81,271 | +14.72% | |
| 2026-02-04 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 12,348 0.0157% | $6.44 | $79,545 | +14.72% | |
| 2026-02-04 | Sale | Herzich Paul | Chief Technology Officer | 10,905 0.0138% | $6.44 | $70,249 | +14.72% | |
| 2026-02-04 | Sale | Ganot Ilan | director | 7,205 0.0091% | $6.44 | $46,414 | +14.72% | |
| 2026-02-02 | Sale | Cumbo Alexander | President and CEO | 80,258 0.1031% | $6.44 | $516,613 | +16.10% | |
| 2026-02-02 | Sale | Howton David T | Chief Operating Officer | 37,771 0.0485% | $6.44 | $243,128 | +16.10% | |
| 2026-02-02 | Sale | Tan Kevin | CFO & Treasurer | 26,837 0.0345% | $6.44 | $172,747 | +16.10% | |
| 2026-02-02 | Sale | Brooks Gabriel | Chief Medical Officer | 28,335 0.0364% | $6.44 | $182,390 | +16.10% | |
| 2026-02-02 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 26,535 0.0341% | $6.44 | $170,803 | +16.10% |
| PERCEPTIVE ADVISORS LLC | 11833539 11.0362% | $74.31M | 5 | 0 | <0.0001% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5034582 4.6953% | $31.62M | 1 | 0 | <0.0001% |
| Adage Capital Management, L.P. | 10 percent owner | 4248084 3.9618% | $26.68M | 1 | 0 | +1.7% |
| RA CAPITAL MANAGEMENT, L.P. | 4192216 3.9097% | $26.33M | 2 | 0 | <0.0001% | |
| Shah Rajeev M. | director | 2689444 2.5082% | $16.89M | 1 | 0 | |
| Koppel Adam | director | 1989444 1.8554% | $12.49M | 1 | 0 | |
| Kahn Clare | director | 2960 0.0028% | $18,588.80 | 2 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 48 | +32.21% | 10M | +12.09% |
| Decreased Positions | 58 | -38.93% | 10M | -12.18% |
| New Positions | 12 | New | 2M | New |
| Sold Out Positions | 10 | Sold Out | 2M | Sold Out |
| Total Postitions | 139 | -6.71% | 82M | -0.09% |
| Perceptive Advisors Llc | $64,493.00 | 15.17% | 11.83M | -73,107 | -0.61% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $43,119.00 | 10.14% | 7.91M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $40,417.00 | 9.51% | 7.42M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $31,672.00 | 7.45% | 5.81M | +100 | +<0.01% | 2025-09-30 |
| Blackrock, Inc. | $25,752.00 | 6.06% | 4.73M | -194,965 | -3.96% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $21,800.00 | 5.13% | 4M | -3M | -40.56% | 2025-09-30 |
| Vanguard Group Inc | $16,807.00 | 3.95% | 3.08M | -281,697 | -8.37% | 2025-09-30 |
| Vestal Point Capital, Lp | $16,214.00 | 3.81% | 2.98M | +1M | +97.67% | 2025-09-30 |
| Fmr Llc | $15,882.00 | 3.74% | 2.91M | -264,273 | -8.31% | 2025-09-30 |
| Citadel Advisors Llc | $14,130.00 | 3.32% | 2.59M | +69,404 | +2.75% | 2025-09-30 |